Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Технологии·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Технологии·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

39% вероятность
Polymarket
НОВОЕ
39% вероятность
Polymarket
НОВОЕ
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron for the SmartDepot long-acting peptide delivery platform continues without a commercial licensing deal, driving the 61.5% market-implied probability of No by the October 7 deadline. The original 14-month evaluation pact signed in October 2024 was extended in December 2025 through October 2026, signaling slower-than-expected progress on applying the PLGA-based microsphere formulation to Lilly’s incretin assets. Recent priorities, including heavy investment in oral GLP-1 candidates like orforglipron and a June 2025 licensing deal for Camurus’ competing FluidCrystal platform, have further tempered trader expectations for a binding technology transfer in the remaining months. No official announcements or regulatory filings have emerged to shift consensus toward Yes.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Объем
$8,224
Дата окончания
7 окт. 2026 г.
Открытие рынка
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron for the SmartDepot long-acting peptide delivery platform continues without a commercial licensing deal, driving the 61.5% market-implied probability of No by the October 7 deadline. The original 14-month evaluation pact signed in October 2024 was extended in December 2025 through October 2026, signaling slower-than-expected progress on applying the PLGA-based microsphere formulation to Lilly’s incretin assets. Recent priorities, including heavy investment in oral GLP-1 candidates like orforglipron and a June 2025 licensing deal for Camurus’ competing FluidCrystal platform, have further tempered trader expectations for a binding technology transfer in the remaining months. No official announcements or regulatory filings have emerged to shift consensus toward Yes.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Объем
$8,224
Дата окончания
7 окт. 2026 г.
Открытие рынка
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

Не доверяй внешним ссылкам.

Часто задаваемые вопросы

«Eli Lilly licenses Peptron’s SmartDepot by October 7?» — это рынок прогнозов на Polymarket, где трейдеры покупают и продают акции «Да» или «Нет» в зависимости от того, верят ли они, что это событие произойдёт. Текущая вероятность по мнению сообщества составляет 39% для «Yes». Например, если «Да» торгуется по 39¢, рынок коллективно оценивает вероятность наступления события в 39%. Эти коэффициенты постоянно меняются по мере реакции трейдеров на новые события и информацию. Акции правильного исхода можно обменять на $1 каждую при разрешении рынка.

«Eli Lilly licenses Peptron’s SmartDepot by October 7?» — недавно созданный рынок на Polymarket, запущен May 6, 2026. Как ранний рынок, это твоя возможность быть среди первых трейдеров, устанавливающих коэффициенты и формирующих начальные ценовые сигналы. Ты также можешь добавить эту страницу в закладки, чтобы следить за объёмом и активностью торгов.

Чтобы торговать на «Eli Lilly licenses Peptron’s SmartDepot by October 7?», просто выбери, считаешь ли ты, что ответ — «Да» или «Нет». Каждая сторона имеет текущую цену, отражающую подразумеваемую вероятность рынка. Введи сумму и нажми «Торговать». Если ты купишь акции «Да» и исход разрешится как «Да», каждая акция принесёт $1. Если исход — «Нет», твои акции «Да» принесут $0. Ты также можешь продать свои акции в любой момент до разрешения, чтобы зафиксировать прибыль или ограничить убыток.

Текущая вероятность для «Eli Lilly licenses Peptron’s SmartDepot by October 7?» составляет 39% для «Yes». Это означает, что сообщество Polymarket в настоящее время оценивает вероятность наступления этого события в 39%. Эти коэффициенты обновляются в реальном времени на основе реальных сделок, предоставляя постоянно обновляемый сигнал ожиданий рынка.

Правила разрешения «Eli Lilly licenses Peptron’s SmartDepot by October 7?» точно определяют, что должно произойти, чтобы каждый исход был объявлен победителем, включая официальные источники данных, используемые для определения результата. Ты можешь просмотреть полные критерии разрешения в разделе «Правила» на этой странице над комментариями. Мы рекомендуем внимательно прочитать правила перед торговлей, так как они определяют точные условия, особые случаи и источники.